HIV-1 envelope glycoprotein complex (HIV-1 Env)

The HIV-1 envelope glycoprotein complex (Env) is a viral surface trimer comprising three gp120 surface glycoproteins non-covalently linked to three gp41 transmembrane subunits[2][4]. This trimeric spike mediates the initial steps of HIV-1 entry into host cells. Attachment begins when gp120 binds to the CD4 receptor on the host cell, inducing conformational changes that allow interaction with a chemokine co-receptor (most commonly CCR5 or CXCR4)[4][6]. Subsequent structural rearrangements in gp41 drive the fusion of the viral and cellular membranes, allowing entry of viral RNA into the host. The Env complex is heavily glycosylated, which shields it from immune recognition, and is a primary target for neutralizing antibodies and entry inhibitors[2]. Its central role in infection and immune evasion makes it a major focus of drug and vaccine development[1][2][3][4].

Other names

HIV-1 EnvHIV-1 envelope spikegp120/gp41 complexenvelope glycoproteinHIV-1 viral entry complex

- CCR5 antagonists (e.g., Maraviroc): block co-receptor binding, prevent viral entry - Fusion inhibitors (e.g., Enfuvirtide): inhibit gp41 conformational change, block membrane fusion - Attachment inhibitors (e.g., Fostemsavir): bind gp120, prevent CD4 binding - Post-attachment inhibitors (e.g., Ibalizumab): bind CD4, block post-attachment steps